353 related articles for article (PubMed ID: 16132345)
41. Antitumor effect of DX-8951, a novel camptothecin analog, on human pancreatic tumor cells and their CPT-11-resistant variants cultured in vitro and xenografted into nude mice.
Takiguchi S; Kumazawa E; Shimazoe T; Tohgo A; Kono A
Jpn J Cancer Res; 1997 Aug; 88(8):760-9. PubMed ID: 9330608
[TBL] [Abstract][Full Text] [Related]
42. pH-dependent uptake of irinotecan and its active metabolite, SN-38, by intestinal cells.
Kobayashi K; Bouscarel B; Matsuzaki Y; Ceryak S; Kudoh S; Fromm H
Int J Cancer; 1999 Nov; 83(4):491-6. PubMed ID: 10508485
[TBL] [Abstract][Full Text] [Related]
43. Reversal of multidrug resistance-associated protein-mediated daunorubicin resistance by camptothecin.
Chauvier D; Kegelaer G; Morjani H; Manfait M
J Pharm Sci; 2002 Aug; 91(8):1765-75. PubMed ID: 12115804
[TBL] [Abstract][Full Text] [Related]
44. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux.
Erlichman C; Boerner SA; Hallgren CG; Spieker R; Wang XY; James CD; Scheffer GL; Maliepaard M; Ross DD; Bible KC; Kaufmann SH
Cancer Res; 2001 Jan; 61(2):739-48. PubMed ID: 11212277
[TBL] [Abstract][Full Text] [Related]
45. Clinical pharmacology of camptothecins.
Iyer L; Ratain MJ
Cancer Chemother Pharmacol; 1998; 42 Suppl():S31-43. PubMed ID: 9750027
[TBL] [Abstract][Full Text] [Related]
46. Clinical pharmacokinetics of irinotecan and its metabolites: a population analysis.
Xie R; Mathijssen RH; Sparreboom A; Verweij J; Karlsson MO
J Clin Oncol; 2002 Aug; 20(15):3293-301. PubMed ID: 12149304
[TBL] [Abstract][Full Text] [Related]
47. Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters.
Chu XY; Kato Y; Ueda K; Suzuki H; Niinuma K; Tyson CA; Weizer V; Dabbs JE; Froehlich R; Green CE; Sugiyama Y
Cancer Res; 1998 Nov; 58(22):5137-43. PubMed ID: 9823324
[TBL] [Abstract][Full Text] [Related]
48. Human immunodeficiency virus protease inhibitors interact with ATP binding cassette transporter 4/multidrug resistance protein 4: a basis for unanticipated enhanced cytotoxicity.
Fukuda Y; Takenaka K; Sparreboom A; Cheepala SB; Wu CP; Ekins S; Ambudkar SV; Schuetz JD
Mol Pharmacol; 2013 Sep; 84(3):361-71. PubMed ID: 23775562
[TBL] [Abstract][Full Text] [Related]
49. Differential cytotoxicity of clinically important camptothecin derivatives in P-glycoprotein-overexpressing cell lines.
Hoki Y; Fujimori A; Pommier Y
Cancer Chemother Pharmacol; 1997; 40(5):433-8. PubMed ID: 9272121
[TBL] [Abstract][Full Text] [Related]
50. Combination therapy with irinotecan and protein kinase C inhibitors in malignant glioma.
Chen TC; Su S; Fry D; Liebes L
Cancer; 2003 May; 97(9 Suppl):2363-73. PubMed ID: 12712458
[TBL] [Abstract][Full Text] [Related]
51. High-performance liquid chromatographic assay with fluorescence detection for the simultaneous measurement of carboxylate and lactone forms of irinotecan and three metabolites in human plasma.
Owens TS; Dodds H; Fricke K; Hanna SK; Crews KR
J Chromatogr B Analyt Technol Biomed Life Sci; 2003 May; 788(1):65-74. PubMed ID: 12668072
[TBL] [Abstract][Full Text] [Related]
52. Breast cancer resistance protein directly confers SN-38 resistance of lung cancer cells.
Kawabata S; Oka M; Shiozawa K; Tsukamoto K; Nakatomi K; Soda H; Fukuda M; Ikegami Y; Sugahara K; Yamada Y; Kamihira S; Doyle LA; Ross DD; Kohno S
Biochem Biophys Res Commun; 2001 Feb; 280(5):1216-23. PubMed ID: 11162657
[TBL] [Abstract][Full Text] [Related]
53. Intestinal alkalization as a possible preventive mechanism in irinotecan (CPT-11)-induced diarrhea.
Ikegami T; Ha L; Arimori K; Latham P; Kobayashi K; Ceryak S; Matsuzaki Y; Bouscarel B
Cancer Res; 2002 Jan; 62(1):179-87. PubMed ID: 11782376
[TBL] [Abstract][Full Text] [Related]
54. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
[TBL] [Abstract][Full Text] [Related]
55. Camptothecin analog (CPT-11)-sensitive human pancreatic tumor cell line QGP-1N shows resistance to SN-38, an active metabolite of CPT-11.
Takeda S; Shimazoe T; Kuga H; Sato K; Kono A
Biochem Biophys Res Commun; 1992 Oct; 188(1):70-7. PubMed ID: 1329748
[TBL] [Abstract][Full Text] [Related]
56. Interaction of oxazaphosphorines with multidrug resistance-associated protein 4 (MRP4).
Zhang J; Ng KY; Ho PC
AAPS J; 2010 Sep; 12(3):300-8. PubMed ID: 20405259
[TBL] [Abstract][Full Text] [Related]
57. Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells.
Yoshikawa M; Ikegami Y; Hayasaka S; Ishii K; Ito A; Sano K; Suzuki T; Togawa T; Yoshida H; Soda H; Oka M; Kohno S; Sawada S; Ishikawa T; Tanabe S
Int J Cancer; 2004 Jul; 110(6):921-7. PubMed ID: 15170677
[TBL] [Abstract][Full Text] [Related]
58. Combination of SN-38 with gefitinib or imatinib overcomes SN-38-resistant small-cell lung cancer cells.
Takigawa N; Takeyama M; Kozuki T; Shibayama T; Hisamoto A; Kiura K; Tada A; Hotta K; Umemura S; Ohashi K; Fujiwara Y; Takata S; Ichihara E; Osawa M; Tabata M; Tanimoto M; Takahashi K
Oncol Rep; 2007 May; 17(5):983-7. PubMed ID: 17390033
[TBL] [Abstract][Full Text] [Related]
59. Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein.
Sugiyama Y; Kato Y; Chu X
Cancer Chemother Pharmacol; 1998; 42 Suppl():S44-9. PubMed ID: 9750028
[TBL] [Abstract][Full Text] [Related]
60. Factors influencing the cellular accumulation of SN-38 and camptothecin.
Cummings J; Boyd G; Macpherson JS; Wolf H; Smith G; Smyth JF; Jodrell DI
Cancer Chemother Pharmacol; 2002 Mar; 49(3):194-200. PubMed ID: 11935211
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
